Acute exacerbation of idiopathic pulmonary fibrosis after bivalent {tozinameran and famtozinameran} mRNA COVID-19 vaccination
Description
An 82-year-old man diagnosed with interstitial lung disease through computed tomography (CT) 1 year prior received a bivalent (tozinameran and famtozinameran) mRNA COVID-19 vaccine. He developed respiratory symptoms 1.5 months later, and chest high
